@article{999ee62d6b7541009b34f06b3c08c7b5,
title = "Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma",
abstract = "Proteasome inhibitors are key parts of our armamentarium against multiple myeloma, but the disease can become resistant through poorly defined mechanisms. In this issue of Cancer Cell, Leung-Hagesteijn and colleagues describe XBP1s- subpopulations of tumor cells that are resistant to bortezomib and may account for therapeutic failures in the clinic.",
author = "Orlowski, {Robert Z.}",
note = "Funding Information: R.Z.O. would like to acknowledge support from the National Cancer Institute in the form of The MD Anderson Cancer Center SPORE in Multiple Myeloma (P50 CA142509) and the Southwest Oncology Group (U10 CA032102). R.Z.O. has received research funding from Bristol-Myers Squibb, Celgene Corporation, Millennium: The Takeda Oncology Company, and Onyx Pharmaceuticals. Also, R.Z.O. has served on advisory boards for Array Biopharma, Bristol-Myers Squibb, Celgene Corporation, Genentech, Merck, Millennium: The Takeda Oncology Company, and Onyx Pharmaceuticals.",
year = "2013",
month = sep,
day = "9",
doi = "10.1016/j.ccr.2013.08.014",
language = "English (US)",
volume = "24",
pages = "275--277",
journal = "Cancer cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "3",
}